Download PDF
Semin Thromb Hemost 2015; 41(06): 563-571
DOI: 10.1055/s-0035-1556588
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Cell Adhesion Molecules: Therapeutic Targets for Inhibition of Inflammatory States

Seamus Allen
1   Department of Molecular and Cellular Therapeutics, Royal College of Surgeons, Ireland
,
Niamh Moran
1   Department of Molecular and Cellular Therapeutics, Royal College of Surgeons, Ireland
› Author Affiliations
Further Information

Publication History

Publication Date:
31 August 2015 (online)

    Permissions and Reprints

Abstract

The diversity of integrins and their complex role in many diseases suggests great potential for this superfamily as drug targets. The initial successes of anti-integrin therapeutics in the treatment of thrombotic disorders suggested that similar anti-integrin agents could be developed for the treatment of inflammatory disorders. While initially a promising strategy, inhibition of the integrins proved to be elusive despite the discovery of highly potent inhibitors. This is due to several reasons, including redundancy among the integrins and the importance of integrins in key physiological systems. Further exploration of the selective role for distinct leukocytic integrins indicated that homing of inflammatory cells to select disease sites depends on a highly regulated expression of discrete integrins and their ligands in limited locations. Selective control of integrin function is also regulated by local chemokines permitting exquisite homing of populations of inflammatory cells to disease sites. A more complete understanding of the regulation of integrin activation in disease states will permit the development of more effective and specific anti-integrin therapeutic agents.

Keywords

inflammation - cell adhesion molecules - therapeutic strategies
 

  • References

  • 1 Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138 (6 Pt 1): 1093-1104
    CrossrefPubMedGoogle Scholar
  • 2 Conrad ME, Umbreit JN, Moore EG. Integrin beta3 blockade with abciximab and protection from myocardial ischemic events. JAMA 1998; 279 (3) 195-196
    PubMedGoogle Scholar
  • 3 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338 (21) 1488-1497
    CrossrefPubMedGoogle Scholar
  • 4 Cho L, Topol EJ, Balog C , et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 2000; 36 (2) 381-386
    CrossrefPubMedGoogle Scholar
  • 5 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69 (1) 11-25
    CrossrefPubMedGoogle Scholar
  • 6 Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003; 2 (9) 703-716
    CrossrefPubMedGoogle Scholar
  • 7 Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994; 14 (2) 195-228
    CrossrefPubMedGoogle Scholar
  • 8 Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007; 8 (5) 215
    CrossrefPubMedGoogle Scholar
  • 9 Alfsen A, Yu H, Magérus-Chatinet A, Schmitt A, Bomsel M. HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. Mol Biol Cell 2005; 16 (9) 4267-4279
    CrossrefPubMedGoogle Scholar
  • 10 Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 2010; 9 (10) 804-820
    CrossrefPubMedGoogle Scholar
  • 11 Todd III RF. The continuing saga of complement receptor type 3 (CR3). J Clin Invest 1996; 98 (1) 1-2
    CrossrefPubMedGoogle Scholar
  • 12 Mould AP, Askari JA, Humphries MJ. Molecular basis of ligand recognition by integrin alpha 5beta 1. I. Specificity of ligand binding is determined by amino acid sequences in the second and third NH2-terminal repeats of the alpha subunit. J Biol Chem 2000; 275 (27) 20324-20336
    CrossrefPubMedGoogle Scholar
  • 13 Springer TA. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc Natl Acad Sci U S A 1997; 94 (1) 65-72
    CrossrefPubMedGoogle Scholar
  • 14 Zhu J, Luo BH, Xiao T, Zhang C, Nishida N, Springer TA. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008; 32 (6) 849-861
    CrossrefPubMedGoogle Scholar
  • 15 Liddington RC, Ginsberg MH. Integrin activation takes shape. J Cell Biol 2002; 158 (5) 833-839
    CrossrefPubMedGoogle Scholar
  • 16 Shimaoka M, Salas A, Yang W, Weitz-Schmidt G, Springer TA. Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity 2003; 19 (3) 391-402
    CrossrefPubMedGoogle Scholar
  • 17 Mould AP, Travis MA, Barton SJ , et al. Evidence that monoclonal antibodies directed against the integrin beta subunit plexin/semaphorin/integrin domain stimulate function by inducing receptor extension. J Biol Chem 2005; 280 (6) 4238-4246
    CrossrefPubMedGoogle Scholar
  • 18 Zhu J, Zhu J, Springer TA. Complete integrin headpiece opening in eight steps. J Cell Biol 2013; 201 (7) 1053-1068
    CrossrefPubMedGoogle Scholar
  • 19 Xiao T, Takagi J, Coller BS, Wang JH, Springer TA. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432 (7013) 59-67
    CrossrefPubMedGoogle Scholar
  • 20 Xiong JP, Stehle T, Zhang R , et al. Crystal structure of the extracellular segment of integrin α Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 2002; 296 (5565) 151-155
    CrossrefPubMedGoogle Scholar
  • 21 Lau TL, Kim C, Ginsberg MH, Ulmer TS. The structure of the integrin alphaIIbbeta3 transmembrane complex explains integrin transmembrane signalling. EMBO J 2009; 28 (9) 1351-1361
    CrossrefPubMedGoogle Scholar
  • 22 Luo BH, Springer TA, Takagi J. A specific interface between integrin transmembrane helices and affinity for ligand. PLoS Biol 2004; 2 (6) e153
    CrossrefPubMedGoogle Scholar
  • 23 Wang W, Zhu J, Springer TA, Luo BH. Tests of integrin transmembrane domain homo-oligomerization during integrin ligand binding and signaling. J Biol Chem 2011; 286 (3) 1860-1867
    CrossrefPubMedGoogle Scholar
  • 24 Yin H, Litvinov RI, Vilaire G , et al. Activation of platelet alphaIIbbeta3 by an exogenous peptide corresponding to the transmembrane domain of alphaIIb. J Biol Chem 2006; 281 (48) 36732-36741
    CrossrefPubMedGoogle Scholar
  • 25 Stephens G, O'Luanaigh N, Reilly D , et al. A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis. J Biol Chem 1998; 273 (32) 20317-20322
    CrossrefPubMedGoogle Scholar
  • 26 Sastry SK, Horwitz AF. Integrin cytoplasmic domains: mediators of cytoskeletal linkages and extra- and intracellular initiated transmembrane signaling. Curr Opin Cell Biol 1993; 5 (5) 819-831
    CrossrefPubMedGoogle Scholar
  • 27 Larkin D, Murphy D, Reilly DF , et al. ICln, a novel integrin alphaIIbbeta3-associated protein, functionally regulates platelet activation. J Biol Chem 2004; 279 (26) 27286-27293
    CrossrefPubMedGoogle Scholar
  • 28 Brophy TM, Raab M, Daxecker H , et al. RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin α(IIb)β3. Biochem Biophys Res Commun 2008; 369 (4) 1088-1093
    CrossrefPubMedGoogle Scholar
  • 29 Liu S, Thomas SM, Woodside DG , et al. Binding of paxillin to α4 integrins modifies integrin-dependent biological responses. Nature 1999; 402 (6762) 676-681
    CrossrefPubMedGoogle Scholar
  • 30 Li A, Guo Q, Kim C, Hu W, Ye F. Integrin αII b tail distal of GFFKR participates in inside-out αII b β3 activation. J Thromb Haemost 2014; 12 (7) 1145-1155
    CrossrefPubMedGoogle Scholar
  • 31 Liu S, Calderwood DA, Ginsberg MH. Integrin cytoplasmic domain-binding proteins. J Cell Sci 2000; 113 (Pt 20): 3563-3571
    PubMedGoogle Scholar
  • 32 Hughes PE, Diaz-Gonzalez F, Leong L , et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem 1996; 271 (12) 6571-6574
    CrossrefPubMedGoogle Scholar
  • 33 Anthis NJ, Haling JR, Oxley CL , et al. Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. J Biol Chem 2009; 284 (52) 36700-36710
    CrossrefPubMedGoogle Scholar
  • 34 Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999; 401 (6755) 808-811
    CrossrefPubMedGoogle Scholar
  • 35 Blystone SD, Williams MP, Slater SE, Brown EJ. Requirement of integrin beta3 tyrosine 747 for beta3 tyrosine phosphorylation and regulation of alphavbeta3 avidity. J Biol Chem 1997; 272 (45) 28757-28761
    CrossrefPubMedGoogle Scholar
  • 36 Sakai T, Zhang Q, Fässler R, Mosher DF. Modulation of beta1A integrin functions by tyrosine residues in the beta1 cytoplasmic domain. J Cell Biol 1998; 141 (2) 527-538
    CrossrefPubMedGoogle Scholar
  • 37 Calderwood DA, Fujioka Y, de Pereda JM , et al. Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc Natl Acad Sci U S A 2003; 100 (5) 2272-2277
    CrossrefPubMedGoogle Scholar
  • 38 Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem 1997; 272 (8) 4651-4654
    CrossrefPubMedGoogle Scholar
  • 39 Vijayan KV, Liu Y, Li TT, Bray PF. Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem 2004; 279 (32) 33039-33042
    CrossrefPubMedGoogle Scholar
  • 40 Gushiken FC, Patel V, Liu Y , et al. Protein phosphatase 2A negatively regulates integrin alpha(IIb)beta(3) signaling. J Biol Chem 2008; 283 (19) 12862-12869
    CrossrefPubMedGoogle Scholar
  • 41 Kato A, Kawamata N, Tamayose K , et al. Ancient ubiquitous protein 1 binds to the conserved membrane-proximal sequence of the cytoplasmic tail of the integrin alpha subunits that plays a crucial role in the inside-out signaling of alpha IIbbeta 3. J Biol Chem 2002; 277 (32) 28934-28941
    CrossrefPubMedGoogle Scholar
  • 42 Liu QY, Corjay M, Feuerstein GZ, Nambi P. Identification and characterization of triosephosphate isomerase that specifically interacts with the integrin alphaIIb cytoplasmic domain. Biochem Pharmacol 2006; 72 (5) 551-557
    CrossrefPubMedGoogle Scholar
  • 43 Deshmukh L, Tyukhtenko S, Liu J, Fox JE, Qin J, Vinogradova O. Structural insight into the interaction between platelet integrin alphaIIbbeta3 and cytoskeletal protein skelemin. J Biol Chem 2007; 282 (44) 32349-32356
    CrossrefPubMedGoogle Scholar
  • 44 Chua GL, Patra AT, Tan SM, Bhattacharjya S. NMR structure of integrin α4 cytosolic tail and its interactions with paxillin. PLoS ONE 2013; 8 (1) e55184
    CrossrefPubMedGoogle Scholar
  • 45 Calderwood DA. Talin controls integrin activation. Biochem Soc Trans 2004; 32 (Pt3): 434-437
    CrossrefPubMedGoogle Scholar
  • 46 Wegener KL, Partridge AW, Han J , et al. Structural basis of integrin activation by talin. Cell 2007; 128 (1) 171-182
    CrossrefPubMedGoogle Scholar
  • 47 Moser M, Legate KR, Zent R, Fässler R. The tail of integrins, talin, and kindlins. Science 2009; 324 (5929) 895-899
    CrossrefPubMedGoogle Scholar
  • 48 Harburger DS, Bouaouina M, Calderwood DA. Kindlin-1 and -2 directly bind the C-terminal region of beta integrin cytoplasmic tails and exert integrin-specific activation effects. J Biol Chem 2009; 284 (17) 11485-11497
    CrossrefPubMedGoogle Scholar
  • 49 Fagerholm SC, Lek HS, Morrison VL. Kindlin-3 in the immune system. Am J Clin Exp Immunol 2014; 3 (1) 37-42
    PubMedGoogle Scholar
  • 50 Takala H, Nurminen E, Nurmi SM , et al. Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood 2008; 112 (5) 1853-1862
    CrossrefPubMedGoogle Scholar
  • 51 Hart R, Stanley P, Chakravarty P, Hogg N. The kindlin 3 pleckstrin homology domain has an essential role in lymphocyte function-associated antigen 1 (LFA-1) integrin-mediated B cell adhesion and migration. J Biol Chem 2013; 288 (21) 14852-14862
    CrossrefPubMedGoogle Scholar
  • 52 Gruda R, Brown AC, Grabovsky V , et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood 2012; 120 (19) 3915-3924
    CrossrefPubMedGoogle Scholar
  • 53 Moretti FA, Moser M, Lyck R , et al. Kindlin-3 regulates integrin activation and adhesion reinforcement of effector T cells. Proc Natl Acad Sci U S A 2013; 110 (42) 17005-17010
    CrossrefPubMedGoogle Scholar
  • 54 Morrison VL, MacPherson M, Savinko T, Lek HS, Prescott A, Fagerholm SC. The β2 integrin-kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo. Blood 2013; 122 (8) 1428-1436
    CrossrefPubMedGoogle Scholar
  • 55 Kasirer-Friede A, Kang J, Kahner B, Ye F, Ginsberg MH, Shattil SJ. ADAP interactions with talin and kindlin promote platelet integrin αIIbβ3 activation and stable fibrinogen binding. Blood 2014; 123 (20) 3156-3165
    CrossrefPubMedGoogle Scholar
  • 56 Hayward AR, Harvey BA, Leonard J, Greenwood MC, Wood CB, Soothill JF. Delayed separation of the umbilical cord, widespread infections, and defective neutrophil mobility. Lancet 1979; 1 (8126) 1099-1101
    PubMedGoogle Scholar
  • 57 Crowley CA, Curnutte JT, Rosin RE , et al. An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med 1980; 302 (21) 1163-1168
    CrossrefPubMedGoogle Scholar
  • 58 Marlin SD, Morton CC, Anderson DC, Springer TA. LFA-1 immunodeficiency disease. Definition of the genetic defect and chromosomal mapping of alpha and beta subunits of the lymphocyte function-associated antigen 1 (LFA-1) by complementation in hybrid cells. J Exp Med 1986; 164 (3) 855-867
    CrossrefPubMedGoogle Scholar
  • 59 Etzioni A, Harlan JM, Pollack S, Phillips LM, Gershoni-Baruch R, Paulson JC. Leukocyte adhesion deficiency (LAD) II: a new adhesion defect due to absence of sialyl Lewis X, the ligand for selectins. Immunodeficiency 1993; 4 (1-4) 307-308
    PubMedGoogle Scholar
  • 60 Etzioni A. Defects in the leukocyte adhesion cascade. Clin Rev Allergy Immunol 2010; 38 (1) 54-60
    CrossrefPubMedGoogle Scholar
  • 61 Larson RS, Hibbs ML, Springer TA. The leukocyte integrin LFA-1 reconstituted by cDNA transfection in a nonhematopoietic cell line is functionally active and not transiently regulated. Cell Regul 1990; 1 (4) 359-367
    PubMedGoogle Scholar
  • 62 Schürpf T, Springer TA. Regulation of integrin affinity on cell surfaces. EMBO J 2011; 30 (23) 4712-4727
    CrossrefPubMedGoogle Scholar
  • 63 Peroni DG, Djukanović R, Bradding P , et al. Expression of CD44 and integrins in bronchial mucosa of normal and mildly asthmatic subjects. Eur Respir J 1996; 9 (11) 2236-2242
    CrossrefPubMedGoogle Scholar
  • 64 Zimmerman T, Blanco FJ. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action. Curr Pharm Des 2008; 14 (22) 2128-2139
    CrossrefPubMedGoogle Scholar
  • 65 Plow EF, Zhang L. A MAC-1 attack: integrin functions directly challenged in knockout mice. J Clin Invest 1997; 99 (6) 1145-1146
    CrossrefPubMedGoogle Scholar
  • 66 Solovjov DA, Pluskota E, Plow EF. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J Biol Chem 2005; 280 (2) 1336-1345
    CrossrefPubMedGoogle Scholar
  • 67 Noti JD, Johnson AK, Dillon JD. The leukocyte integrin gene CD11d is repressed by gut-enriched Kruppel-like factor 4 in myeloid cells. J Biol Chem 2005; 280 (5) 3449-3457
    CrossrefPubMedGoogle Scholar
  • 68 Noti JD. Expression of the myeloid-specific leukocyte integrin gene CD11d during macrophage foam cell differentiation and exposure to lipoproteins. Int J Mol Med 2002; 10 (6) 721-727
    PubMedGoogle Scholar
  • 69 Miyazaki Y, Bunting M, Stafforini DM , et al. Integrin alphaDbeta2 is dynamically expressed by inflamed macrophages and alters the natural history of lethal systemic infections. J Immunol 2008; 180 (1) 590-600
    CrossrefPubMedGoogle Scholar
  • 70 Postigo AA, Pulido R, Campanero MR , et al. Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active alpha 4 beta 1-fibronectin receptors upon B cell activation. Eur J Immunol 1991; 21 (10) 2437-2445
    CrossrefPubMedGoogle Scholar
  • 71 Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1: 154-188
    PubMedGoogle Scholar
  • 72 Marazuela M, Postigo AA, Acevedo A, Díaz-González F, Sanchez-Madrid F, de Landázuri MO. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur J Immunol 1994; 24 (10) 2483-2490
    CrossrefPubMedGoogle Scholar
  • 73 Laschinger M, Engelhardt B. Interaction of alpha4-integrin with VCAM-1 is involved in adhesion of encephalitogenic T cell blasts to brain endothelium but not in their transendothelial migration in vitro. J Neuroimmunol 2000; 102 (1) 32-43
    CrossrefPubMedGoogle Scholar
  • 74 Sun H, Liu J, Zheng Y, Pan Y, Zhang K, Chen J. Distinct chemokine signaling regulates integrin ligand specificity to dictate tissue-specific lymphocyte homing. Dev Cell 2014; 30 (1) 61-70
    CrossrefPubMedGoogle Scholar
  • 75 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339 (7) 436-443
    CrossrefPubMedGoogle Scholar
  • 76 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330 (14) 956-961
    CrossrefPubMedGoogle Scholar
  • 77 Artoni A, Li J, Mitchell B , et al. Integrin β3 regions controlling binding of murine mAb 7E3: implications for the mechanism of integrin alphaIIbbeta3 activation. Proc Natl Acad Sci U S A 2004; 101 (36) 13114-13120
    CrossrefPubMedGoogle Scholar
  • 78 Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007; 13 (1) 79-95
    CrossrefPubMedGoogle Scholar
  • 79 Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64 (8) 1336-1342
    CrossrefPubMedGoogle Scholar
  • 80 Fedyk ER, Wyant T, Yang LL , et al. Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis 2012; 18 (11) 2107-2119
    CrossrefPubMedGoogle Scholar
  • 81 Yao K, Gagnon S, Akhyani N , et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS ONE 2008; 3 (4) e2028
    CrossrefPubMedGoogle Scholar
  • 82 Bloomgren G, Richman S, Hotermans C , et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366 (20) 1870-1880
    CrossrefPubMedGoogle Scholar
  • 83 Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol 1997; 158 (5) 2099-2106
    PubMedGoogle Scholar
  • 84 Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014; 147 (5) 981-989
    CrossrefPubMedGoogle Scholar
  • 85 Garnock-Jones KP. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease. Bio Drugs 2015; 29 (1) 57-67
    PubMedGoogle Scholar
  • 86 Jullien D, Prinz JC, Langley RG , et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208 (4) 297-306
    CrossrefPubMedGoogle Scholar
  • 87 Frampton JE, Plosker GL. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am J Clin Dermatol 2009; 10 (1) 51-72
    CrossrefPubMedGoogle Scholar
  • 88 Wang LC, Wang IH, Jou JR. Optic neuritis secondary to Angiostrongylus cantonensis infection. Ocul Immunol Inflamm 2006; 14 (3) 189-191
    CrossrefPubMedGoogle Scholar
  • 89 Vanderslice P, Woodside DG. Integrin antagonists as therapeutics for inflammatory diseases. Expert Opin Investig Drugs 2006; 15 (10) 1235-1255
    CrossrefPubMedGoogle Scholar
  • 90 Halland N, Blum H, Buning C, Kohlmann M, Lindenschmidt A. Small Macrocycles As Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett 2014; 5 (2) 193-198
    CrossrefPubMedGoogle Scholar
  • 91 Grove RA, Shackelford S, Sopper S , et al. Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. Eur J Neurol 2013; 20 (7) 1032-1042
    CrossrefPubMedGoogle Scholar
  • 92 Sedgwick JB, Jansen KJ, Kennedy JD, Kita H, Busse WW. Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions. J Allergy Clin Immunol 2005; 116 (4) 812-819
    CrossrefPubMedGoogle Scholar